8 completed, 4 unknown, 3 terminated, 2 active not recruiting. 19 Phase 2, 5 Phase 1, 5 Phase 3.
Follow Eye Abnormalities: new trials by email Literature Review of Eye Abnormalities trials Research Report on Eye Abnormalities
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene No intervention, will not receive any active study intervention, Intravitreal Injection of Ultevursen - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Not yet recruiting | Laboratoires Thea | 81 | 2026-10-05 | 2026-09-01 |
| Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene Intravitreal Injection of Ultevursen, No intervention, will not receive any active study intervention - Retinitis Pigmentosa (RP), Usher Syndrome Type 2 | Phase 2 | Active not recruiting | Laboratoires Thea | 81 | 2024-12-11 | 2026-07-09 |
| Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration CLS-AX, Aflibercept - Neovascular Age-related Macular Degeneration | Phase 2 | Completed | Clearside Biomedical, Inc. | 60 | 2023-05-31 | 2025-07-25 |
| Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste) QR-421a, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 5 | 2021-12-15 | 2024-08-07 |
| Study to Evaluate the Efficacy Safety and Tolerability of Ultevursen in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene (Sirius) Ultevursen, Sham-procedure - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 2 / Phase 3 | Terminated | Laboratoires Thea | 7 | 2021-12-08 | 2024-07-12 |
| Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy Bromfenac Sodium - Familial Exudative Vitreoretinopathies | Phase 2 | Unknown | Seoul National University Hospital | 39 | 2021-11-01 | 2023-11-22 |
| A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101 QLS-101ophthalmic solution 1%, QLS-101ophthalmic solution 2% - Sturge-Weber Syndrome (SWS), Glaucoma | Phase 2 | Completed | Qlaris Bio, Inc. | 3 | 2021-10-19 | 2025-01-20 |
| RAFT - Clinical Trial of RAFT for Aniridia Related Keratopathy RAFT-OS - Aniridia | Phase 1 / Phase 2 | Completed | University College, London | 9 | 2021-07-28 | 2025-04-30 |
| An Open-label, Dose Escalation and Double-masked, Randomized, Controlled Trial Evaluating Safety and Tolerability of Sepofarsen in Children (<8 Years of Age) With LCA10 Caused by Mutations in the CEP290 Gene. sepofarsen - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Unknown | ProQR Therapeutics | 15 | 2021-03-23 | 2022-03-25 |
| Single Ascending Dose Study in Participants With LCA10 EDIT-101 - Leber Congenital Amaurosis 10, Inherited Retinal Dystrophies | Phase 1 / Phase 2 | Unknown | Editas Medicine, Inc. | 34 | 2019-09-26 | 2022-12-05 |
| Extension Study to Study PQ-110-001 (NCT03140969) QR-110 - Leber Congenital Amaurosis 10, Blindness | Phase 1 / Phase 2 | Terminated | Laboratoires Thea | 9 | 2019-05-13 | 2024-10-15 |
| A Study to Evaluate Efficacy, Safety, Tolerability and Exposure After a Repeat-dose of Sepofarsen (QR-110) in LCA10 (ILLUMINATE) sepofarsen, Sham - Leber Congenital Amaurosis 10, Blindness | Phase 2 / Phase 3 | Active not recruiting | ProQR Therapeutics | 36 | 2019-04-04 | 2022-03-17 |
| Study to Evaluate Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene QR-421a, Sham-procedure (dose cohort 1&2 only) - Retinitis Pigmentosa, Usher Syndrome Type 2 | Phase 1 / Phase 2 | Completed | ProQR Therapeutics | 20 | 2019-03-06 | 2022-04-20 |
| A Phase 2 Open Label Extension Study in Participants With Nonsense Mutation Aniridia Ataluren - Aniridia | Phase 2 | Withdrawn | PTC Therapeutics | 2018-12-31 | 2019-10-07 | |
| Study of Ataluren in Participants With Nonsense Mutation Aniridia Ataluren, Placebo - Aniridia | Phase 2 | Completed | PTC Therapeutics | 39 | 2016-01-31 | 2022-05-27 |
| Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis 4 mg CLS-TA, 0.8 mg CLS-TA - Uveitis, Macular Edema | Phase 2 | Completed | Clearside Biomedical, Inc. | 22 | 2014-10-01 | 2021-02-08 |
| Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis triamcinolone acetonide (Triesence®) - Uveitis, Intermediate Uveitis | Phase 1 / Phase 2 | Completed | Clearside Biomedical, Inc. | 11 | 2013-02-01 | 2021-02-21 |
| Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma Latanoprost, Dorzolamide - Childhood Glaucoma | Phase 2 | Completed | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 37 | 2009-07-01 | 2019-09-27 |
| Prosthetic Motility and Complications in Pegged Versus Unpegged Hydroxyapatite Orbital Implants orbital implant - Anophthalmos, Orbital Implants | Phase 2 / Phase 3 | Unknown | Shahid Beheshti University of Medical Sciences | 50 | 2005-11-01 | 2010-05-12 |
Retinal Diseases (9) · Vision Disorders (9) · Eye Diseases, Hereditary (8) · Eye Diseases (6) · Retinitis Pigmentosa (5) · Usher Syndromes (5) · Leber Congenital Amaurosis (4) · Leber Congenital Amaurosis 10 (4) · Meckel Syndrome, Type 4 (4) · Aniridia (3) · Blindness (3) · Choroidal Effusions (3) · Neurologic Manifestations (3) · Sensation Disorders (3)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (16) · Congenital Abnormalities (15) · Eye Diseases (13) · Genetic Diseases, Inborn (11) · Nervous System Diseases (11) · Pathological Conditions, Signs and Symptoms (10) · Signs and Symptoms (9) · Neurologic Manifestations (6) · Retinal Degeneration (6) · Sensation Disorders (6) · Uveal Diseases (6) · Abnormalities, Multiple (5) · Blindness (5) · Deaf-Blind Disorders (5)
Intravitreal Injections (3) · ataluren (2) · Adrenal Cortex Hormones (1) · Latanoprost (1) · Orbital Implants (1) · Triamcinolone (1) · Triamcinolone Acetonide (1) · aflibercept (1) · bromfenac (1) · dorzolamide (1) · salicylhydroxamic acid (1)
Laboratoires Thea (5) · Clearside Biomedical, Inc. (3) · ProQR Therapeutics (3) · PTC Therapeutics (2) · Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (1) · Editas Medicine, Inc. (1) · Qlaris Bio, Inc. (1) · Seoul National University Hospital (1) · Shahid Beheshti University of Medical Sciences (1) · University College, London (1)
United States (12) · United Kingdom (6) · Canada (5) · Belgium (4) · Germany (4) · Italy (4) · Netherlands (4) · Brazil (3) · France (3) · Denmark (1) · Iran (1) · South Korea (1)
Thomas Ciulla, MD (2) · B. Wirostko, M.D. (1) · Babak Babsharif, MD (1) · Jeong Hun Kim, MD, PhD (1) · Julie Daniels (1) · Luciano Quaranta, MD (1) · Quintus Ngumah, OD, PhD (1) · Sajjad Ahmad (1) · Susan Coultas, PhD (1)
PMID 27312975, PMID 27980877, PMID 28957960, PMID 31215818, PMID 33497524, PMID 34629400, PMID 37418643, PMID 38709228, PMID 40339601, PMID 42490097
2018 (3), 2008 (1)